This is the Hottest Biotech ETF to Start 2024
After two years of underperforming, the biotech sector appears to be rebounding with a strong performance in the Loncar Cancer Immunotherapy ETF (CNCR)
After two years of underperforming, the biotech sector appears to be rebounding with a strong performance in the Loncar Cancer Immunotherapy ETF (CNCR)